Looking at approximately 326,000 SNPs in 1,053 Swedish subjects, the study is thought to be the first "sufficiently powered" trial to detect genome-wide significance of three SNPs. As a result, study authors note that "additional genes having a major influence on warfarin dose might not exist or be found in the near-term."
In separate interviews, researchers at Baylor College of Medicine, Signature Genomic Laboratories, and the Children's Hospital of Philadelphia recently discussed how new arrays sold by Agilent, Affy, and Illumina affect their cytogenetics services.
Although the developers note that the protocol particularly benefits the sequencing of AT-rich genomes, they say that it is also quicker than the standard method, which requires PCR amplification, and "should be used routinely to prepare libraries for Genome Analyzer sequencing."
The company is looking to differentiate itself from other players in the miRNA array market — such as Agilent Technologies, Life Technologies, Exiqon, and Febit — by stressing the "quality, performance, and affordability" of its OneArray platform.
The company last month presented data showing that the test could be used to detect cancer, but more work is needed to refine the test so that it can distinguish between different types of malignancies.
Both companies are offering users of second-generation sequencing systems new tools to select portions of the genome for targeted resequencing but have optimized their products for different sequencing platforms.
Researchers from the Murdoch Childrens Research Institute in Parkville, Australia, investigated the feasibility of replacing "time-consuming, locus-specific testing for specific microdeletion and microduplication syndromes with microarray analysis." Study co-author Howard Slater spoke with BioArray News about the paper.